|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Bevacizumab Combined With Chemotherapy Prolongs Survival for Some Patients with Advanced Lung Cancer
Researchers at the National Cancer Institute have released the “preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer [showing] that those patients who received bevacizumab (Avastin™) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.”
Patients who received standard chemotherapy in combination with Avastin “had a median overall survival of 12.5 months compared to patients treated with the standard chemotherapy alone, who had a median survival of 10.2 months…Detailed results from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) to be held in Orlando, Fla., on May 13-17, 2005.”
Designer or “targeted” cancer treatments like Avastin work by "targeting molecular pathways critical to the growth and survival of cancer cells” and represent some of the most promising new treatments for cancer.
|home spotlight commentary research events news about contact links archives|